LOW INFLIXIMAB TROUGH LEVELS AT WEEK 6 AND 14 IN AN ASIAN INFLAMMATORY BOWEL DISEASE COHORT ARE NOT ASSOCIATED WITH POORER CLINICAL OUTCOME

被引：0
|
作者：
Lim, Chong Teik
Koh, Samantha J.
Tay, Shu Wen
Salazar, Ennaliza
Chan, Pak Wo
Tan, Malcolm
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
EP1307
引用
收藏
页码：S1095 / S1096
页数：2
相关论文
共 50 条
  • [21] Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients
    Zelinkova, Z.
    Lipovska, A.
    Otottova, K.
    Lucenicova, J.
    Kadleckova, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S460 - S461
  • [22] INFLIXIMAB PEAK AND 1-WEEK SERUM LEVEL ESTIMATES PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Hellstrom, Per M.
    Saaed, Hiwa
    Hernandez, Armando
    Touny, Aya A.
    Webb, Dominic-Luc
    Fogdell-Hahn, Anna
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S804 - S805
  • [23] Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab
    Orfanoudaki, E.
    Gazouli, M.
    Foteinogiannopoulou, K.
    Theodouraki, E.
    Legaki, E.
    Koutroubakis, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S330 - S331
  • [24] Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
    O'Connell, J.
    McDonagh, P.
    Hazel, K.
    Fiona, J.
    Dunne, C.
    Farrell, R.
    Harewood, G.
    Hartery, K.
    Kelly, O.
    MacCarthy, F.
    McKiernan, S.
    Murray, F.
    O'Morain, C.
    Aoibhlinn, O.
    Kevans, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S473 - S473
  • [25] Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
    Choi, So Yoon
    Kang, Ben
    Lee, Jee Hyun
    Choe, Yon Ho
    [J]. GUT AND LIVER, 2017, 11 (01) : 55 - 61
  • [26] INFLIXIMAB TROUGH LEVELS AFTER INDUCTION THERAPY: A PREDICTIVE FACTOR FOR OUTCOME IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    van Hoeve, Karen
    Hoffman, Ilse
    Dreesen, Erwin
    Ferrante, Marc
    Ann, Gils
    Vermeire, Severine
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S1042 - S1043
  • [27] Influence of initial albumin levels on infliximab and adalimumab trough levels in inflammatory bowel disease patients
    Gonzalez-Lopez, J.
    Llamas, C.
    Giraldez-Montero, J. M.
    Ferreiro, R.
    Baston, I.
    Lamas, M. J.
    Dominguez-Munoz, J. E.
    Barreiro-de Acosta, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S248 - S249
  • [28] High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
    Wilson, Aze
    Choi, Bethany
    Sey, Michael
    Ponich, Terry
    Beaton, Melanie
    Kim, Richard B.
    [J]. BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [29] High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
    Aze Wilson
    Bethany Choi
    Michael Sey
    Terry Ponich
    Melanie Beaton
    Richard B. Kim
    [J]. BMC Gastroenterology, 21
  • [30] Infliximab in inflammatory bowel disease:: clinical outcome in a population based cohort from Stockholm County
    Ljung, T
    Karlén, P
    Schmidt, D
    Hellström, PM
    Lapidus, A
    Janczewska, I
    Sjöqvist, U
    Löfberg, R
    [J]. GUT, 2004, 53 (06) : 849 - 853
12345